Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network
IL23is are associated with a lower risk of PsA incidence compared to IL17is in PsO patients, particularly in specific age, sex, and ethnic groups. These findings suggest that IL23is may be more suitable for PsO patients at high risk of PsA and could inform potential updates to treatment guidelines. Further research should focus on refining therapeutic strategies by incorporating patient-specific factors such as comorbidities, ethnicity, and genetic predispositions, which could optimize biologic selection and enhance PsA prevention efforts in clinical practice.
Authors
- James Cheng‐Chung Wei (ORCID: https://orcid.org/0000-0002-1235-0679)
- Yu‐Hsun Wang (ORCID: https://orcid.org/0000-0002-4937-6119)
- An‐Ping Huo (ORCID: https://orcid.org/0000-0002-8285-1700)
- Sebastian Yu (ORCID: https://orcid.org/0000-0002-2955-458X)
Institutions
- Asia University (TW)
- Kaohsiung Medical University (TW)
- National Taiwan University (TW)
- China Medical University (TW)
- Kaohsiung Medical University Chung-Ho Memorial Hospital (TW)
- Chung Shan Medical University Hospital (TW)
- Shanxi Academy of Medical Sciences (CN)
- Chung Shan Medical University (TW)
Publication Details
- Journal
- BioDrugs
- Published
- 2025-01-29
- DOI
- https://doi.org/10.1007/s40259-025-00705-5
- Citations
- 8
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 6.38
Funders
- National Science and Technology Council